In yesterday’s Wall Street session, Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares traded at $15.19, down -8.71% from the previous session.
DAWN stock price is now -0.25% away from the 50-day moving average and 12.32% away from the 200-day moving average. The market capitalization of the company currently stands at $1.33B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $30 to $33, Needham maintained Buy rating for Day One Biopharmaceuticals Inc (NASDAQ: DAWN). On April 25, 2023, BofA Securities Downgraded its previous ‘Buy’ rating to ‘Underperform’ on the stock reducing its target price from $34 to quote $9, while ‘CapitalOne’ rates the stock as ‘Overweight’
In other news, Blackman Samuel C., HEAD OF R&D sold 10,000 shares of the company’s stock on Apr 18 ’24. The stock was sold for $160,163 at an average price of $16.02. Upon completion of the transaction, the HEAD OF R&D now directly owns 1,174,662 shares in the company, valued at $17.84 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 25 ’24, HEAD OF R&D Blackman Samuel C. sold 10,000 shares of the business’s stock. A total of $160,055 was realized by selling the stock at an average price of $16.01. This leaves the insider owning 1,184,662 shares of the company worth $18.0 million. A total of 32.55% of the company’s stock is owned by insiders.
During the past 12 months, Day One Biopharmaceuticals Inc has had a low of $9.67 and a high of $17.85. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 12.72, and a quick ratio of 12.72.
Day One Biopharmaceuticals Inc(DAWN) Company Profile
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
